Neurocrine Biosciences
NBIX
#1579
Rank
HK$107.20 B
Marketcap
HK$1,075
Share price
1.15%
Change (1 day)
-8.10%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): HK$33.60

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$33.67. In 2024 the company made an earnings per share (EPS) of HK$26.41 an increase over its 2023 EPS that were of HK$19.84.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$33.6027.22%
2024HK$26.4133.07%
2023HK$19.8457.76%
2022HK$12.5869.47%
2021HK$7.42-78.21%
2020HK$34.06990%
2019HK$3.1381.82%
2018HK$1.72-113.5%
2017-HK$12.730.62%
2016-HK$12.6657.28%
2015-HK$8.0525.61%
2014-HK$6.4118.84%
2013-HK$5.39-1085.71%
2012HK$0.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$13.44-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$10.56-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$160.30 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$0.23-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.86-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$13.36-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$233.60-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$13.80-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK